Zobrazeno 1 - 9
of 9
pro vyhledávání: '"J M Hilden"'
Publikováno v:
Journal of Pediatric Hematology/Oncology. 18:182-186
Purpose : Patients treated for Hodgkin disease (HD) are at increased risk for developing secondary neoplasms, including non-Hodgkin lymphoma (NHL). We present a patient who developed NHL (brain and lungs) as a second malignancy together with recurren
Publikováno v:
Blood. 82:1080-1085
The chromosomal translocation, t(4;11)(q21;q23), is the most common type of 11q23 chromosomal abnormality, being highly prevalent in infant acute leukemias and associated with a poor prognosis. The t(4;11) results in the fusion of an 11q23 gene (MLL,
Autor:
Rukhmi Bhat, Alan S. Gamis, John D. Crispino, J M Hilden, Sébastien Malinge, Rhett P. Ketterling, Martin S. Tallman, Elisabeth Paietta, April D. Sorrell
Publikováno v:
Leukemia. 23:2159-2160
Publikováno v:
Medical and pediatric oncology. 30(3)
Medullary dysplasia may be present in the kidneys of children with the Beckwith-Wiedemann Syndrome (BWS). This is usually visible only at the microscopic level, but superimposed pyelonephritis in a child with the BWS led to gross changes that produce
Autor:
J M, Hilden, F O, Smith, J L, Frestedt, R, McGlennen, W B, Howells, P H, Sorensen, D C, Arthur, W G, Woods, J, Buckley, I D, Bernstein, J H, Kersey
Publikováno v:
Blood. 89(10)
To study prognostic factors in infant acute myeloid leukemia (AML), we analyzed 44 children treated on Childrens Cancer Group protocols for MLL gene rearrangement by Southern blot, cytogenetic 11q23 abnormalities, and reactivity with monoclonal antib
Publikováno v:
Blood. 86(10)
Molecular techniques to detect MLL (11q23) and AF-4 (4q21) gene rearrangements are being evaluated for use in stratification of patients into prognostic groups. We studied 15 cases of infant acute lymphoblastic leukemia (ALL) with Southern blotting f
Publikováno v:
Journal of Clinical Oncology. 25:12507-12507
12507 Background: Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant tumor of the central nervous system (CNS) in childhood, comprising up to 20% of malignant CNS tumors in patients < 3 years old. Although aggressive approaches including
Autor:
D. A. Singer, J. M. Hilden, J. Finklestein, E. Sandler, K. W. Chan, K. M. Shannon, E. Mantadakis
Publikováno v:
Journal of Pediatric Hematology/Oncology. 20:377
Autor:
J M, HILDEN
Publikováno v:
Ugeskrift for laeger. 123